PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-44.93%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-66.71%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-101.66%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-101.66%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-71.47%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-71.18%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-70.30%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
No Data
No Data available this quarter, please select a different quarter.
-2.14%
Reduced diluted shares while VET is at 0.68%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-37.35%
Firm’s AR is declining while VET shows 18.85%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
25.90%
We show growth while VET is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
3.27%
Asset growth well under 50% of VET's 6.66%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
0.67%
Under 50% of VET's 5.58%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
49.64%
Debt growth far above VET's 14.28%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
-64.45%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.